Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Nutraceuticals in 2017

Nutraceuticals in endocrine disorders

Nutraceuticals are gaining legitimacy and their potential clinical role is expanding. Data from 2017 provides evidence for their possible use in type 2 diabetes mellitus, the metabolic syndrome, obesity, dyslipidaemia and osteoporosis. Ongoing high-quality research in this area might justify future selective implementation of nutraceuticals into general health practice.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015).

    CAS  Article  Google Scholar 

  2. 2

    Marazzi, G. et al. Comparison of low-dose statin versus low-dose statin + armolipid plus in high-untensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE trial). Am. J. Cardiol. 120, 893–897 (2017).

    CAS  Article  Google Scholar 

  3. 3

    Lloyd-Jones, D. M. et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J. Am. Coll. Cardiol. 70, 1785–1822 (2017).

    Article  Google Scholar 

  4. 4

    Jamilian, M. & Asemi, Z. The effects of soy isoflavones on metabolic status of patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 101, 3386–3394 (2016).

    CAS  Article  Google Scholar 

  5. 5

    Lambert, M. N. T. et al. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. Am. J. Clin. Nutr. 106, 909–920 (2017).

    CAS  PubMed  Google Scholar 

  6. 6

    Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).

    CAS  Article  Google Scholar 

  7. 7

    Nicolucci, A. C. et al. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology 153, 711–722 (2017).

    Article  Google Scholar 

  8. 8

    Comerford, K. B. Recent developments in multivitamin/mineral research. Adv. Nutr. 4, 644–656 (2013).

    CAS  Article  Google Scholar 

  9. 9

    Dibaba, D. T. et al. The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 106, 921–929 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    Kjaer, T. N. et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 102, 1642–1651 (2017).

    Article  Google Scholar 

Download references


A.J.B. is supported by the Clinical Investigator Program at the Schulich School of Medicine & Dentistry, Western University and by the Fernand Labrie Fellowship of the Canadian Society for Endocrinology. R.A.H. has received operating grants from the Canadian Institutes of Health Research (Foundation Grant), the Heart and Stroke Foundation of Ontario (G-15-0009214), and Genome Canada through Genome Quebec (award 4530).

Author information



Corresponding author

Correspondence to Robert A. Hegele.

Ethics declarations

Competing interests

A.J.B. declares no competing interests. R.A.H. has received honoraria for membership on advisory boards and speakers' bureaus for Akcea/Ionis, Aegerion, Amgen, Gemphire, Regeneron, Sanofi and Valeant.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Berberich, A., Hegele, R. Nutraceuticals in endocrine disorders. Nat Rev Endocrinol 14, 68–70 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing